NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
11.30
-0.53 (-4.48%)
At close: Nov 16, 2026, 4:00 PM EST
11.83
+0.53 (4.70%)
Pre-market: Nov 17, 2026, 8:18 AM EST
NovoCure Revenue
NovoCure had revenue of $193.40M in the quarter ending September 30, 2026, with 15.67% growth. This brings the company's total for the last twelve months to $725.39M, up 12.94% year-over-year. In the year 2025, NovoCure had annual revenue of $655.35M with 8.28% growth. That makes NovoCure the 9,230th largest company in the world by revenue and 2,048th in the United States.
Revenue (ttm)
$725.39M
Revenue Growth
+12.94%
P/S Ratio
1.82
Revenue / Employee
$451,955
Employees
1,605
Market Cap
1.32B
Revenue by Geography
- United States 385.63M 58.8%
- Germany 79.41M 12.1%
- France 76.19M 11.6%
- Other International Markets 56.90M 8.7%
- Japan 37.79M 5.8%
- Greater China 19.44M 3.0%
Fiscal year ended Dec 31, 2025 See the full NovoCure breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 655.35M | 50.13M | 8.28% |
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.67M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
| Dec 31, 2018 | 248.07M | 71.04M | 40.13% |
| Dec 31, 2017 | 177.03M | 94.14M | 113.57% |
| Dec 31, 2016 | 82.89M | 49.80M | 150.52% |
| Dec 31, 2015 | 33.09M | 17.60M | 113.60% |
| Dec 31, 2014 | 15.49M | 5.13M | 49.53% |
| Dec 31, 2013 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enovis | 2.31B |
| Integra LifeSciences Holdings | 1.66B |
| CONMED | 1.37B |
| Tandem Diabetes Care | 1.08B |
| Lumexa Imaging Holdings | 1.06B |
| Inspire Medical Systems | 880.94M |
| Alphatec Holdings | 839.72M |
| PROCEPT BioRobotics | 352.31M |
NVCR News
- 3 days ago - Novocure announces publication of data analysis from Phase 3 PANOVA-3 trial - TheFly
- 3 days ago - JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer - Business Wire
- 6 days ago - Novocure price target raised to $31 from $27 at Ladenburg - TheFly
- 8 days ago - Novocure receives Not Approvable Letter from FDA for PMA app for Optune Mya - TheFly
- 8 days ago - Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer - Business Wire
- 18 days ago - Novocure price target lowered to $20 from $23 at Evercore ISI - TheFly
- 18 days ago - Novocure’s Pax disrupted by Revolution rollout, says Wedbush - TheFly
- 19 days ago - NovoCure Earnings Call Transcript: Q3 2026 - Transcripts